IRLA
IRulya Therapeutics Inc.
Set alert
32.95 USD +1.33 +4.21%
30.00 Day range 34.26
16.00 52-week range 880.00
- YTD
- -95.08%
- 1 year
- -90.02%
- Open
- 30.67
- Prev close
- 31.62
- Mkt cap
- 33.51M
- Vol
- 98.00K
- Avg vol
- 42.42K
- EPS
- -214.01
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 30.00
- High
- 34.26
Financial health
Altman Z-Score
-5.16 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C-1 / 5 overall
- DCF 1
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 4
Valuation
P/E -2.0×
FY 2017 5y median -1.4× FY 2025
P/S 0.0×
FY 2017 5y median 0.0× FY 2025
P/B -4.7×
FY 2017 5y median 0.5× FY 2025
P/FCF -4.0×
FY 2017 5y median -2.5× FY 2025
EV/EBITDA -2.2×
FY 2017 5y median -2.2× FY 2025
EV/Sales 0.0×
FY 2017 5y median 0.0× FY 2025
FCF Yield -24.9%
FY 2017 5y median -39.8% FY 2025
Profitability
Gross Margin 0.0%
FY 2017 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2017 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2017 5y median 0.0% FY 2025
ROE 235.1%
FY 2017 5y median -51.4% FY 2025
ROIC -73.7%
FY 2017 5y median -53.4% FY 2025
ROA -89.8%
FY 2017 5y median -49.7% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2017 FY 2025
Operating Income 12.0%
FY 2017 FY 2025
EPS (diluted) -28.2%
FY 2017 FY 2025
Free Cash Flow -29.9%
FY 2017 FY 2025
Financial Health
Current Ratio 0.5×
FY 2017 5y median 7.9× FY 2025
Quick Ratio 0.5×
FY 2017 5y median 7.9× FY 2025
Debt / Equity -0.5×
FY 2017 5y median 0.0× FY 2025
Net Debt / EBITDA -0.2×
FY 2017 5y median 0.3× FY 2025
Interest Coverage 0.0×
FY 2017 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2017 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2017 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31